IOL Chemicals and Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	9.3yrs
Gemiddelde ambtstermijn bestuur	4.6yrs

Recente managementupdates

Recent updates

CEO

IOL Chemicals and Pharmaceuticals heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Pardeep Khanna	Chief Financial Officer	9.3yrs	₹15.80m	geen gegevens
Abhay Singh	VP, Company Secretary & Compliance Officer	5yrs	₹7.40m	geen gegevens
Varinder Gupta	MD & Whole Time Director	17.2yrs	₹98.57m	2.04% ₹ 474.8m
Vikas Gupta	Joint Managing Director & Executive Director	9.5yrs	₹30.06m	geen gegevens
Kushal Rana	Director of Works & Wholetime Director	no data	₹17.07m	geen gegevens
Abhiraj Gupta	Executive Director	1.6yrs	₹12.99m	geen gegevens
Nikhil Gupta	President	no data	geen gegevens	geen gegevens
Gurupur Pai	Chief Technology Officer	no data	geen gegevens	geen gegevens
Damandeep Singh	President of Project	no data	₹780.00k	geen gegevens
Kamlesh Ranbhan	President of R&D	no data	geen gegevens	geen gegevens
Gopal Singla	President of Engineering	no data	geen gegevens	geen gegevens
Praveen Hans	President of API Business	no data	geen gegevens	geen gegevens

9.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 524164 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Varinder Gupta	MD & Whole Time Director	18.4yrs	₹98.57m	2.04% ₹ 474.8m
Vikas Gupta	Joint Managing Director & Executive Director	1.6yrs	₹30.06m	geen gegevens
Kushal Rana	Director of Works & Wholetime Director	3.4yrs	₹17.07m	geen gegevens
Abhiraj Gupta	Executive Director	1.6yrs	₹12.99m	geen gegevens
Rajender Malla	Independent Chairman of the Board	5.8yrs	₹500.00k	geen gegevens
Sharad Tyagi	Additional Independent Director	2.5yrs	₹1.15m	geen gegevens
Harpal Singh	Independent Director	5.8yrs	₹750.00k	geen gegevens
Sandhya Mehta	Independent Director	10.3yrs	₹1.05m	geen gegevens

4.6yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 524164 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

IOL Chemicals and Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Vikas Vij as Chief Executive Officer, Effective 30 September 2024

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Sandhya Mehta as Independent Director

IOL Chemicals and Pharmaceuticals Limited, Annual General Meeting, Aug 23, 2024

IOL Chemicals and Pharmaceuticals Limited Announces Executive Changes

President of Project recently sold ₹3.5m worth of stock

IOL Chemicals and Pharmaceuticals Limited Appoints Sanjay Chaturvedi as Chief Executive Officer

Recent updates

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Vikas Vij as Chief Executive Officer, Effective 30 September 2024

Investor sentiment improves as stock rises 21%

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Sandhya Mehta as Independent Director

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited, Annual General Meeting, Aug 23, 2024

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2024 Results on May 14, 2024

Price target increased by 15% to ₹517

IOL Chemicals and Pharmaceuticals Limited Announces CDE, China Approved Metformin Hydrochloride

IOL Chemicals and Pharmaceuticals Limited Approves Closing of M/S Iol Global Limited, Uk, Wholly Owned Subsidiary of the Company

IOL Chemicals and Pharmaceuticals Limited Approves Closing of M/S Iol Global Limited, Uk, Wholly Owned Subsidiary of the Company

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Second quarter 2024 earnings released: EPS: ₹6.45 (vs ₹2.71 in 2Q 2023)

New major risk - Revenue and earnings growth

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment improves as stock rises 17%

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 13% to ₹510

IOL Chemicals and Pharmaceuticals Receives Cep for Paracetamol to Export in European Market

Full year 2023 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 19%

Upcoming dividend of ₹4.00 per share at 1.3% yield

Third quarter 2023 earnings released: EPS: ₹4.05 (vs ₹6.82 in 3Q 2022)

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Fiscal Year 2023, Payable Before 8 March 2023

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 07, 2023

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹2.71 (vs ₹5.26 in 2Q 2022)

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Receives EDQM Certification to Supply Pantoprazole Sodium Sesquihydrate API in European Market

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 14, 2022

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

Now 20% undervalued

IOL Chemicals and Pharmaceuticals Limited Announces Executive Changes

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Commences the Commercial Production of 'Paracetamol' with Installed Capacity of 1,800 MTPA Along with Backward Integration of Para Amino Phenol (PAP) with Effect from 22 April 2022

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Now 23% undervalued after recent price drop

Upcoming dividend of ₹4.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Financial Year 2021-222, Payable Before 5 March 2022

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 04, 2022

Upcoming dividend of ₹2.00 per share

President of Project recently sold ₹3.5m worth of stock

First quarter 2022 earnings released: EPS ₹11.41 (vs ₹22.30 in 1Q 2021)

Full year 2021 earnings released: EPS ₹76.21 (vs ₹63.51 in FY 2020)

Joint MD & Whole Time Director has left the company

IOL Chemicals and Pharmaceuticals Limited Appoints Sanjay Chaturvedi as Chief Executive Officer

Investor sentiment improved over the past week

New 90-day low: ₹659

Third quarter 2021 earnings released: EPS ₹19.54 (vs ₹17.22 in 3Q 2020)

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 10, 2021

Ind-Swift Labs' Promoters Reportedly Sound Out PEs to Sell Their Stake

Upcoming Dividend of ₹4.00 Per Share

Second quarter 2021 earnings released: EPS ₹21.61

New 90-day low: ₹655

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2021 Results on Nov 06, 2020

New 90-day low: ₹700

New 90-day high - ₹833

First quarter earnings released

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2021 Results on Jul 31, 2020

CEO

Leiderschapsteam